Pharmacokinetics, Serum Stability and Immunogenicity of A Polypeptide Inhibitor of B2GPI/Antibody Complexes Tested in Mice.

@article{Porter2012PharmacokineticsSS,
  title={Pharmacokinetics, Serum Stability and Immunogenicity of A Polypeptide Inhibitor of B2GPI/Antibody Complexes Tested in Mice.},
  author={Andrew J. Porter and N. Beglova},
  journal={Blood},
  year={2012},
  volume={120},
  pages={2205-2205}
}
  • Andrew J. Porter, N. Beglova
  • Published 2012
  • Medicine
  • Blood
    • Abstract 2205 Background: Antiphospholipid syndrome (APS) is an autoimmune disease with clinical features of thrombosis and pregnancy loss. Beta2-glycoprotein I (B2GPI) is the major antigen for APS-related antibodies. We engineered a polypeptide consisting of two ligand-binding A1 modules from the ApoE receptor 2. Previously, we demonstrated that this polypeptide, A1-A1, preferentially binds B2GPI/antibody complexes compared to B2GPI alone and efficiently inhibits the binding of B2GPI/antibody… CONTINUE READING
    View via Publisher